FDA lifts IND for ARD-101, resuming PWS clinical activities in 2027
Aardvark reported $60.3M in cash, halted HERO trial findings indicate positive trends, and expects to resume operations in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed